Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1: A systematic review and meta-analysis of randomised controlled trials

Amirhossein Sahebkar, C. Catena, K.K. Ray, A.J. Vallejo-Vaz, Ž. Reiner, L.A. Sechi, G.L. Colussi

    Research output: Contribution to journalArticle

    13 Citations (Scopus)

    Abstract

    © Schattauer 2016.Elevated plasma levels of the pro-thrombotic and pro-inflammatory factor plasminogen activator inhibitor-1 (PAI-1) may contribute to the pathogenesis of atherosclerotic cardiovascular disease. Beyond their lipid-lowering effect, statins have been shown to modulate plasma PAI-1 levels but evidence from individual randomised controlled trials (RCTs) is controversial. Therefore, we aimed to assess the potential effects of statin therapy on plasma PAI-1 concentration through a meta-analysis of RCTs. We searched Medline and SCOPUS databases (up to October 3, 2014) to identify RCTs investigating the effect of statin therapy on plasma PAI-1 concentrations. We performed random-effects meta-analysis and assessed heterogeneity (I2 test, subgroup and sensitivity analyses) and publication bias (funnel plot, Egger and "trim and fill" tests). Sixteen RCTs (comprising 19 treatment arms) were included and pooled analyses showed a significant effect of statins in reducing plasma PAI-1 concentrations (weighted mean difference WMD: -15.72 ng/ml, 95 % confidence interval [CI]: -25.01, -6.43,). In subgroup analysis, this effect remained significant in with lipophilic statins (atorvastatin and simvastatin) (WMD: -21.32 ng/ml, 95 % CI: -32.73, -9.91, I2=99 %) and particularly atorvastatin (WMD: -20.88 ng/mL, 95 % CI: -28.79, -12.97, I2=97 %). In the meta-regression analysis, the impact of statins on PAI-1 did not correlate with the administered dose, duration of treatment and changes in plasma LDL-cholesterol concentrations. Finally, evidence of publication bias was observed. In conclusion, taking into account the limit of heterogeneity between studies, the present meta-analysis suggests that statin therapy (mainly atorvastatin) significantly lowers plasma PAI-1 concentrations.
    Original languageEnglish
    Pages (from-to)162-171
    JournalThrombosis and Haemostasis
    Volume116
    Issue number1
    DOIs
    Publication statusPublished - 2016

    Fingerprint Dive into the research topics of 'Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1: A systematic review and meta-analysis of randomised controlled trials'. Together they form a unique fingerprint.

  • Cite this